Neuralstem Inc. (CUR) Receives New Coverage from Analysts at Brean Capital
Brean Capital started coverage on shares of Neuralstem Inc. (NASDAQ:CUR) in a research report sent to investors on Tuesday morning. The brokerage issued a buy rating and a $4.00 target price on the stock.
Separately, Roth Capital reissued a buy rating and issued a $1.20 price target on shares of Neuralstem in a report on Friday, September 23rd.
Shares of Neuralstem (NASDAQ:CUR) opened at 0.3185 on Tuesday. The company’s market capitalization is $36.55 million. Neuralstem has a 12-month low of $0.19 and a 12-month high of $1.35. The firm’s 50-day moving average is $0.29 and its 200-day moving average is $0.38.
Neuralstem (NASDAQ:CUR) last issued its earnings results on Thursday, August 11th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm earned $2.50 million during the quarter, compared to analyst estimates of $2.50 million. Neuralstem had a negative net margin of 173,849.97% and a negative return on equity of 574.32%. On average, equities analysts predict that Neuralstem will post ($0.17) EPS for the current year.
Several large investors have recently made changes to their positions in the company. Sabby Management LLC purchased a new stake in shares of Neuralstem during the second quarter worth about $1,893,000. Vanguard Group Inc. increased its stake in shares of Neuralstem by 21.8% in the second quarter. Vanguard Group Inc. now owns 3,384,138 shares of the company’s stock worth $984,000 after buying an additional 606,500 shares during the last quarter. Finally, Blair William & Co. IL purchased a new stake in shares of Neuralstem during the second quarter worth about $122,000. 18.20% of the stock is currently owned by hedge funds and other institutional investors.
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.